Our findings demonstrate that IGFBP‐4 exerts antifibrotic effects in vitro, ex vivo, and in vivo, and its levels are reduced in primary pulmonary fibroblasts of patients with SSc‐associated pulmonary fibrosis. This evidence concerns the gene IGFBP4 and systemic sclerosis.